5AM Venture Management, LLC
An institutional investment manager in SAN FRANCISCO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1799883.
- Reported value$287.9m
- Positions16
Holdings: 16 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Maplight Therapeutics IncMPLT | COM | 56565P103 | 34.0 | 11.8% | 950,011 | Unchanged | |
| Tyra Biosciences IncTYRA | COM | 90240B106 | 32.9 | 11.4% | 1,029,298 | Unchanged | |
| Entrada Therapeutics IncTRDA | COM | 29384C108 | 29.9 | 10.4% | 4,056,379 | Unchanged | |
| Pharvaris N V | COM | N69605108 | 27.6 | 9.6% | 797,600 | Unchanged | |
| CAMP4 Therapeutics CorpCAMP | COM | 13463J101 | 25.6 | 8.9% | 5,869,091 | Unchanged | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 22.8 | 7.9% | 2,353,304 | Unchanged | |
| Tectonic Therapeutic IncTECX | COM | 878972108 | 20.9 | 7.2% | 606,660 | Unchanged | |
| Zentalis Pharmaceuticals IncZNTL | COM | 98943L107 | 19.1 | 6.7% | 3,947,913 | Unchanged | |
| Celldex Therapeutics Inc NewCLDX | COM NEW | 15117B202 | 18.5 | 6.4% | 497,270 | Unchanged | |
| Eyepoint IncEYPT | COM NEW | 30233G209 | 15.0 | 5.2% | 1,050,000 | Unchanged | |
| Biohaven Ltd | COM | G1110E107 | 11.0 | 3.8% | 738,972 | Unchanged | |
| Surrozen IncSRZN | COM NEW | 86889P208 | 7.0 | 2.4% | 271,250 | Reduced−116,250 | |
| Skye Bioscience Inc | COM NEW | 83086J200 | 6.7 | 2.3% | 9,681,763 | Unchanged | |
| ALX Oncology Holdings IncALXO | COM | 00166B105 | 6.3 | 2.2% | 3,057,325 | Unchanged | |
| Protara Therapeutics IncTARA | COM STK | 74365U107 | 5.2 | 1.8% | 1,369,782 | Unchanged | |
| Silence Therapeutics plcSLN | ADS | 82686Q101 | 5.2 | 1.8% | 476,200 | Unchanged |
Sold out: 4 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−580,945 | |
| Erasca IncERAS | COM | 29479A108 | 0.0 | 0.0% | 0 | Sold out−3,485,971 | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 0.0 | 0.0% | 0 | Sold out−572,665 | |
| Rallybio CorpRLYB | COM | 75120L209 | 0.0 | 0.0% | 0 | Sold out−291,788 |
Source: SEC EDGAR, Form 13F-HR, accession 0001799883-26-000003 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.